The authors report a pilot study of a new approach for the topical treatment of onychomycosis using physiologic principles of fungal growth and serial debridement. In total, 154 patients were studied for 1 year with mild, moderate, and severe nail disease. Negative mycologic cultures in these 3 groups were 100%, 65%, and 35%, respectively. All patients reported subjective improvement in the first 3 months.
Gupta AK, Fleckman P., Baran R.Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis . J Am Acad Dermatol. 2000;43:S70-S80.
2.
Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continous terbinafine for onychomycosis: a randomized, double-blind control trial. J Am Acad Dermatol. 2005;53:578-584.
3.
Baran R., Hay R., Haneke E., Tosti A.Onychomycosis: The Current Approach to Diagnosis and Therapy. 2nd ed. London, England: Taylor & Francis; 2006.
4.
Fisher AAContact Dermatitis. 3rd ed. Philadelphia: Lea & Febiger; 1986.5. Crissey JT, Lang H., Parish LCManual of Medical Mycology. Cambridge, MA: Blackwell Science; 1995.
5.
Mark HF, Bikales NMEncyclopedia of Polymer Science and Engineering. 2nd ed., vols 1-2. New York, NY: Wiley; 1985.
6.
Gupta AKEvaluating ciclopirox nail lacquer, oral antifungal agents, and other measures in the management of onychomycosis. Cutis. 2004;74:1S,4.
7.
Gupta AK, Lynch L.Management of onychomycosis: examining the role of mono-therapy and dual, triple, or quadruple therapies. Cutis. 2004 ;74:1S,5.
8.
Ghannoun MA, Hajjeh RA, Scher R., et al. A large scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution and antifungal susceptibility patterns. J Am Acad Dermatol. 2004;43:641-648.
9.
Gupta AK, Gover MD, Nouri K., et al. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048-1071.
10.
Finch JJ, Warshaw EMToenail onychomycosis: current and future treatment options. Dermatol Ther. 2007;20:31-46.
